A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1)

NCT06218511 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

BIOLOGICAL: Peptide-based hepatocellular carcinoma vaccine IMA970A
COMBINATION_PRODUCT: Durvalumab
OTHER: Montanide (Adjuvant)

Sponsor

National Cancer Institute, Naples